Home » Stocks » HBIO

Harvard Bioscience, Inc. (HBIO)

Stock Price: $4.39 USD 0.19 (4.52%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $4.49 +0.10 (2.28%) Jan 22, 4:49 PM
Market Cap 163.70M
Revenue (ttm) 102.09M
Net Income (ttm) -6.65M
Shares Out 38.92M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE 14.79
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.39
Previous Close $4.20
Change ($) 0.19
Change (%) 4.52%
Day's Open 4.21
Day's Range 4.14 - 4.45
Day's Volume 166,082
52-Week Range 1.42 - 4.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 weeks ago

HOLLISTON, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (“Harvard Bioscience”) today announced the refinancing of its debt with the closing of a new $65 mil...

GlobeNewsWire - 2 months ago

HOLLISTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participat...

Seeking Alpha - 2 months ago

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

HOLLISTON, MA., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens...

GlobeNewsWire - 4 months ago

HOLLISTON, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelli...

Seeking Alpha - 5 months ago

Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

HOLLISTON, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens...

GlobeNewsWire - 7 months ago

Provides Update on Performance Against Previously Announced Strategic Plan Provides Update on Performance Against Previously Announced Strategic Plan

Seeking Alpha - 8 months ago

Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Drab Near-Term Prospects for Scientific Instruments Industry

Other stocks mentioned: MTD, PKI, WAT
Zacks Investment Research - 8 months ago

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -125.00% and -15.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the...

Zacks Investment Research - 8 months ago

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

The S&P 500 posted solid gains of 20.8%, 18% and 10.4% in the 12-month period after the first occurrence of SARS, MERS and Ebola back in 2003, 2013 and 2014, respectively.

Other stocks mentioned: BBW, GRBK, KGC, MEI
GlobeNewsWire - 9 months ago

Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

GlobeNewsWire - 9 months ago

Company will continue to manufacture and ship innovative products for global development and research throughout crisis Company will continue to manufacture and ship innovative products for gl...

Seeking Alpha - 10 months ago

Harvard Bioscience, Inc.'s (HBIO) CEO Jim Green on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Scientific Instruments Industry Outlook: Prospects Look Good

Other stocks mentioned: MTD, PKI, WAT
Zacks Investment Research - 1 year ago

Harvard Bioscience has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

Harvard Bioscience (HBIO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Seeking Alpha - 1 year ago

Harvard Bioscience, Inc. (HBIO) CEO Jim Green on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of 0.00% and -3.80%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the...

GlobeNewsWire - 1 year ago

HOLLISTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular ...

GlobeNewsWire - 1 year ago

HOLLISTON, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Tech...

Zacks Investment Research - 1 year ago

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

HOLLISTON, Mass., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Sys...

Zacks Investment Research - 1 year ago

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Harvard Bioscience's (HBIO) CEO Jim Green on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Harvard Bioscience, Inc. (HBIO) CEO Jeffrey Duchemin on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Harvard Bioscience (HBIO) delivered earnings and revenue surprises of -33.33% and -0.95%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the s...

Zacks Investment Research - 1 year ago

Harvard Bioscience (HBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About HBIO

Harvard Bioscience develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also ... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Dec 7, 2000
CEO
James W. Green
Employees
505
Stock Exchange
NASDAQ
Ticker Symbol
HBIO
Full Company Profile

Financial Performance

In 2019, HBIO's revenue was $116.18 million, a decrease of -3.81% compared to the previous year's $120.77 million. Losses were -$4.69 million, 60.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for HBIO stock is "Strong Buy." The 12-month stock price forecast is 5.75, which is an increase of 30.98% from the latest price.

Price Target
$5.75
(30.98% upside)
Analyst Consensus: Strong Buy